Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome
Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome
复制标题
DOI：
10.3851/imp3002
复制
发表时间：
2016-01-01
影响因子：
1.2
通讯作者：
Jang, Hee-Chang
中科院分区：
文献类型：
--
作者：
Kim, Uh Jin;Won, Eun-Jeong;Jang, Hee-Chang
自2012年沙特阿拉伯首次报告中东呼吸综合征（MERS）以来，尽管中东呼吸综合征冠状病毒（CoV）毒性强，病死率高，但尚未制定标准治疗指南。2015年在韩国爆发的疫情表明，中东呼吸综合征疫情可能发生在中东以外。利巴韦林和干扰素- α联合使用是这种感染最广泛使用的治疗方法。然而，由于这些药物治疗的结果不同，迫切需要一种新的抗病毒联合方案。这是一个使用洛匹那韦/利托那韦联合抗病毒治疗中东呼吸综合征冠状病毒感染患者的病例报告。
Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-alpha has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.